Halaven reimbursed in France, but EU prices reflect austerity and delay

Eisai's end-of-life breast cancer drug Halaven (eribulin) has won reimbursement in France. The firm has welcomed the news, although the price is not quite what it had hoped for, commented Nick Burgin, Eiasi's European marketing director. Meanwhile, procedural delays in getting the drug to market in Spain and Ireland are dragging on, along with the deepening financial crisis.

Halaven is now available in France for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. The Transparency Commission...